These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cost-effectiveness of reduced follow-up in malignant melanoma. Hengge UR; Wallerand A; Stutzki A; Kockel N J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672 [TBL] [Abstract][Full Text] [Related]
7. A rational approach to the follow-up of melanoma patients. Garbe C Recent Results Cancer Res; 2002; 160():205-15. PubMed ID: 12079215 [TBL] [Abstract][Full Text] [Related]
9. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Alexandrescu DT Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451 [TBL] [Abstract][Full Text] [Related]
11. Changing trends in melanoma treatment and the expanding role of the dermatologist. Brown MD; Johnson TM; Swanson NA Dermatol Clin; 1991 Oct; 9(4):657-67. PubMed ID: 1934641 [TBL] [Abstract][Full Text] [Related]
12. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Francken AB; Shaw HM; Accortt NA; Soong SJ; Hoekstra HJ; Thompson JF Ann Surg Oncol; 2007 Jun; 14(6):1924-33. PubMed ID: 17357855 [TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. Garbe C; Paul A; Kohler-Späth H; Ellwanger U; Stroebel W; Schwarz M; Schlagenhauff B; Meier F; Schittek B; Blaheta HJ; Blum A; Rassner G J Clin Oncol; 2003 Feb; 21(3):520-9. PubMed ID: 12560444 [TBL] [Abstract][Full Text] [Related]
15. [Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up]. Francken AB; Thompson JF; Bastiaannet E; Hoekstra HJ Ned Tijdschr Geneeskd; 2008 Mar; 152(10):557-62. PubMed ID: 18402322 [TBL] [Abstract][Full Text] [Related]
16. Staging work-up and post-treatment surveillance of patients with melanoma. Olson JA; Jaques DP; Coit DG; Hwu WJ Clin Plast Surg; 2000 Jul; 27(3):377-90, viii. PubMed ID: 10941559 [TBL] [Abstract][Full Text] [Related]
17. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. Leiter U; Buettner PG; Eigentler TK; Bröcker EB; Voit C; Gollnick H; Marsch W; Wollina U; Meier F; Garbe C J Am Acad Dermatol; 2012 Jan; 66(1):37-45. PubMed ID: 21700361 [TBL] [Abstract][Full Text] [Related]
18. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Hofmann U; Szedlak M; Rittgen W; Jung EG; Schadendorf D Br J Cancer; 2002 Jul; 87(2):151-7. PubMed ID: 12107834 [TBL] [Abstract][Full Text] [Related]
19. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589 [TBL] [Abstract][Full Text] [Related]
20. [Malignant melanoma: which examinations are useful in staging and follow-up?]. Goerz G; Schulte-Beerbühl R; Roder K; Schoppe WD; Münchhoff C; Jungblut RM Dtsch Med Wochenschr; 1986 Aug; 111(33):1230-3. PubMed ID: 3527640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]